Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz
“I am excited to welcome Marella and look forward to drawing from her extensive strategy development, corporate finance and operational experience. She brings industry-leading financial acumen and we look forward to working with her as we continue to commercialize VOWST and advance SER-155 toward a clinical readout,” said
“I would like to thank my Seres colleagues and the board of directors for the opportunity to serve as Seres’s CFO and to support the launch of VOWST as the first-ever FDA-approved oral microbiome therapeutic,” said
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements about the executive transitions, the continued growth of VOWST, the success of our clinical studies and product candidates and other statements which are not historical fact.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have incurred significant losses, are not currently profitable and may never become profitable; our need for additional funding; our limited operating history; our novel approach to therapeutic intervention; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product or product candidates and develop and commercialize our product or product candidates, if approved; the unknown degree and competing factors of market acceptance for VOWST; the competition we will face; our ability to protect our intellectual property; and our ability to retain key personnel and to manage our growth. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240226791948/en/
Investor and Media:
Rwindsor@serestherapeutics.com
Source: